L
Ludger Dinkelborg
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 84
Citations - 4862
Ludger Dinkelborg is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: In vivo & Biodistribution. The author has an hindex of 32, co-authored 83 publications receiving 4361 citations. Previous affiliations of Ludger Dinkelborg include ETH Zurich & Bayer.
Papers
More filters
Journal ArticleDOI
Molecular imaging in drug development
TL;DR: The applications of molecular Imaging in drug development are reviewed, highlighting successes and identifying key challenges that need to be addressed for successful integration of molecular imaging into the drug development process.
Journal ArticleDOI
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Christopher C. Rowe,Uwe Ackerman,William J Browne,Rachel S. Mulligan,Kerryn L Pike,Graeme O'Keefe,H. J. Tochon-Danguy,Gordon Chan,Salvatore U Berlangieri,Gareth Jones,Kerryn L Dickinson-Rowe,H Kung,Wei Zhang,Mei-Ping Kung,Daniel Skovronsky,Thomas Dyrks,Gerhard Holl,Sabine Krause,Matthias Friebe,Lutz Lehman,Stefanie Lindemann,Ludger Dinkelborg,Colin L. Masters,Victor L. Villemagne +23 more
TL;DR: F-BAY94-9172 PET discriminates between AD and FTLD or healthy controls and might facilitate integration of Abeta imaging into clinical practice.
Journal ArticleDOI
Application of locked nucleic acids to improve aptamer in vivo stability and targeting function
Kathrin Schmidt,Sandra Borkowski,Jens Kurreck,Andrew Stephens,Rolf Bald,Maren Hecht,Matthias Friebe,Ludger Dinkelborg,Volker A. Erdmann +8 more
TL;DR: The strategy to introduce LNA modifications after the selection procedure is likely to be generally applicable to improve the in vivo stability of aptamers without compromising their binding properties.
Journal ArticleDOI
A high-affinity human antibody that targets tumoral blood vessels
Lorenzo Tarli,Enrica Balza,Enrica Balza,Francesca Viti,Francesca Viti,Laura Borsi,Laura Borsi,Patrizia Castellani,Patrizia Castellani,Dietmar Berndorff,Dietmar Berndorff,Ludger Dinkelborg,Ludger Dinkelborg,Dario Neri,Dario Neri,Luciano Zardi,Luciano Zardi +16 more
TL;DR: Findings quantitatively show that new-forming blood vessels can selectively be targeted in vivo using specific antibodies, and suggest that L19 may be of clinical utility for the immunoscintigraphic detection of angiogenesis in patients.
Journal ArticleDOI
Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
Heiko Kroth,Felix Oden,Jérôme Molette,Hanno Schieferstein,Francesca Capotosti,Andre Mueller,Mathias Berndt,Heribert Schmitt-Willich,Vincent Darmency,Emanuele Gabellieri,Cédric Boudou,Tanja Juergens,Yvan Varisco,Efthymia Vokali,David T. Hickman,Gilles Tamagnan,Andrea Pfeifer,Ludger Dinkelborg,Andreas Muhs,Andrew W. Stephens +19 more
TL;DR: Preclinical data of all ten fluoropyridine regioisomers attached to the pyrrolo[2,3-b:4,5-c’]dipyridine scaffold is presented, revealing compounds 4 and 7 with superior properties, and the lead candidate [18F]PI-2620 (compound 7) displayed high affinity for tau deposits in AD brain homogenate competition assays and showed excellent selectivity with no off-target binding to